Public Board papers 31.03.22

EXECUTIVE SUMMARY

Introduction

The Integrated Performance, Quality & Finance report presents a summary dashboard that provides an overview of performance. S afe

• One serious incident was reported in February and two previous incidents were stepped down following serious incident panels, details of which can be found on slide 7. There was 1 incident reported with the classification of death, 1 as major and 4 as moderate in February, details of which can be found on slide 8. All the incidents are still progressing through to full root cause analysis. No never events were reported in month.

• Slides 9 & 10 provide details of shared learning from incidents following Executive Reviews. • There are 3 Trust level risks scored at 15+. Details of these can be found on slide 13. Responsive

• The 62 day cancer waiting time standards have not been met in February with performance in month at 76.0% for 62 days and 74.0% for upgrades. There was improvement against the 24 day standard 83.0%. The number of patients waiting over 104 days as at the end of the month remains high but has reduced from January. The majority of these patients are referred to the Trust over day 100. All 31 day targets and 18 week RTT standards have been achieved in February. Performance against all the CWT thresholds is constantly monitored. • The Trust will be reviewing the new models of care and measurement following the release of the Clinicaly-led review of NHS standards published 9th March 22 • Referrals in February increased from January but remained slightly below the 19/20 comparison average. At month 11 cumulative referrals in 21/22 are on course to be back at 19/20 levels by the end of the financial year. • Activity levels in most areas are above GM recovery plans and in some areas consistent with or above 19/20 levels. New attendances are showing as above 19/20 levels, as are outpatient follow ups. Chemotherapy deliveries are also slightly above 19/20 levels. Surgical operations and radiotherapy fractions remain behind 19/20 levels. Effective • There have been no cases of MRSA bacteraemia. There have been 3 cases of C-Difficile that were attributable to the trust in February with no lapses in care identified. • There were no cases of hospital acquired nosocomial Covid-19 infections in February. • Workforce metrics are below the set thresholds all departments and developing their improvement plans currently. Well – Led • The Trust position as at month 11 is a year to date surplus of £1.076m (in month deficit of £653k against an agreed nil balance control total for the year which reflects the new GM financial arrangements in place for M1-12). • The month 11 I&E surplus is £17.411m, prior to adjusting for donated depreciation, charitably funded capital donations, donated grant income and impairments. • The cash balance is £167,227k. • The Trust is showing a Capital underspend at Month 11 of £7,930k, which equates to 9.0% underperformance against the NHSEI plan and £4,146k (-4.9%) underperformance against the reduced £2.5m NHSI plan. The main expenditure incurred has been on the Paterson development, the Macclesfield satellite, the tiered car park and progress on the Carbon Energy Fund infrastructure improvement programme (both Trust and government grant funded). 23